Novartis posts encouraging results for Sjögren’s syndrome therapy
Novartis: good results for Sjögren's syndrome remedy
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Novartis posts encouraging results for Sjögren’s syndrome therapy
Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease.
This content was published on
2 minutes
Keystone-SDA
Italiano
it
Novartis: buoni risultati per rimedio Sindrome di Sjögren
Original
In the phase III trials Neptunus-1 and Neptunus-2, the therapy reduced disease activity in patients, a statement said today. The data will now be presented at a medical congress and forwarded to health authorities worldwide.
Ianalumab has the potential to become the only targeted treatment for patients with Sjögren’s Syndrome, according to Novartis. According to experts, the product could bring the group more than CHF1 billion ($1.24 billion) per year in the future.
Ianalumab (VAY736) is a next-generation human antibody that could treat several B-cell-related diseases, including the aforementioned Sjögren’s Syndrome, but also immune thrombocytopenia (PTI) and systemic lupus erythematosus (SLE). The therapy is the result of a collaboration with Morphosys, a company acquired by Novartis in 2024.
Translated from Italian by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
Related Stories
Popular Stories
More
Swiss Politics
United States’ ‘second lady’ observes Swiss training system
Switzerland could produce up to 5Mt of emissions annually by 2050
This content was published on
Two to five megatonnes of CO2 equivalents per year: this is the amount of greenhouse gas emissions that Switzerland is still expected to produce annually in 2050, a new study shows.
US tariffs putting 100,000 jobs at risk in Switzerland
This content was published on
US tariffs of 39% on Swiss imports will directly affect 100,000 jobs, mainly in the watchmaking, machinery, metals, and food industries, economiesuisse warns.
This content was published on
Switzerland has released CHF4 million (nearly $5 million) to help Sudan, which has been severely affected by famine and cholera.
Switzerland rejects new Israeli settlements in Palestinian territory
This content was published on
Switzerland says it rejects the announced construction of thousands of housing units in the Israeli-occupied Palestinian West Bank.
Larry Finck and André Hoffmann named interim co-chairs of WEF board
This content was published on
The WEF also revealed an investigation commissioned by the board has cleared its founder Klaus Schwab and his wife of accusations made by anonymous whistleblowers.
Vice-president of German parliament in favour of Switzerland joining EU
This content was published on
The vice-president of the Bundestag says his country should support closer ties between Switzerland and the European Union given the customs conflict with the United States.
Lindt & Sprüngli reportedly considering shifting Easter bunny production to US
This content was published on
Swiss chocolate manufacturer Lindt & Sprüngli could relocate the production of its gold-wrapped Easter bunnies to the US in order to circumvent the import tariffs imposed by the Trump administration.
Swiss petition launched against curbing 30km/h speed limit
This content was published on
The Traffic Club of Switzerland (TCS) has submitted a petition to the Federal Chancellery, challenging the 30km/h speed limit on local roads.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.